Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,843 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dexamethasone/Dexamethasone acetate Clear all
Terminated Phase 3 Interventional Results available

Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

NCT00024167
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Doxorubicin hydrochloride, Estramustine phosphate sodium, Ketoconazole, Prednisone, Vinblastine, Strontium chloride Sr 89, Dexamethasone
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
40
States / cities
Gainesville, Georgia • Savannah, Georgia • Hines, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 23, 2026, 4:29 PM EDT
Completed Phase 3 Interventional Results available

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

NCT00689936
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide and low-dose dexamethasone, Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles, Melphalan, Prednisone and Thalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 23, 2026, 4:29 PM EDT
Withdrawn Phase 4 Interventional

Particulate vs. Nonparticulate Epidural Steroid Injections for Lumbar Foraminal Stenosis

NCT03245671
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
Kenalog Injectable Product, Decadron Phosphate, Injectable, Epidural Steroid Injection
Drug · Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 23, 2026, 4:29 PM EDT
Completed Phase 1 Interventional

Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma

NCT02792036
View directory record Official record
Conditions
Retinoblastoma
Interventions
Carboplatin, Maxitrol®, Focal Therapy, Plaque Radiotherapy
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 23, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

Selinexor Treatment of Refractory Myeloma

NCT02336815
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Dexamethasone
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 23, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma

NCT01559935
View directory record Official record
Conditions
Multiple Myeloma
Interventions
carfilzomib, Dexamethasone, Clarithromycin, Lenalidomide
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 23, 2026, 4:29 PM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

NCT04640168
View directory record Official record
Conditions
COVID-19
Interventions
Baricitinib, Dexamethasone, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
61
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Sep 23, 2026, 4:29 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

NCT05552976
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Mezigdomide, Carfilzomib, Dexamethasone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
34
States / cities
Mobile, Alabama • Cerritos, California • Irvine, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 23, 2026, 4:29 PM EDT
Enrolling by invitation Phase 2 Interventional

DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury

NCT07567274
View directory record Official record
Conditions
Tinnitus
Interventions
DMSO-based otic solution with betahistine, dexamethasone, and lidocaine, DMSO-based transdermal cream with levocarnitine and N-acetylcysteine
Drug
Lead sponsor
Leading Edge Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 23, 2026, 4:29 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Intraoperative Methadone Administration for Improved Pain Control in Spinal Fusion Patients

NCT02989597
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Methadone Hydrochloride, Standard pain regimen, Spinal Fusion Surgery, Dexamethasone, Ketamine, Remifentanil, Sufentanil
Drug · Other · Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 23, 2026, 4:29 PM EDT
Recruiting Phase 2 Interventional

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

NCT06616597
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma), Metastatic Prostate Cancer
Interventions
Abiraterone acetate, Dexamethasone, Metronidazole
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 23, 2026, 4:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

ATRA and Carfilzomib in Plasma Cell Myeloma Patients

NCT06536413
View directory record Official record
Conditions
Multiple Myeloma
Interventions
All-Trans Retinoic Acid (ATRA) Dose 0, All-Trans Retinoic Acid (ATRA) Dose 1
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 23, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

ALL Adult Consortium Trial: Adult ALL Trial

NCT00476190
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Doxorubicin, Cytarabine, Methotrexate, Vincristine, Cyclophosphamide, Methylprednisone, Hydrocortisone Sodium Succinate, Dexamethasone, 6-MP, PEG-Asparaginase, Imatinib, Etoposide, Radiation Therapy, E. coli Asparaginase
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
7
States / cities
Boston, Massachusetts • New York, New York • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 23, 2026, 4:29 PM EDT
Completed Phase 1 Interventional

Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors

NCT01170897
View directory record Official record
Conditions
Solid Tumor
Interventions
PEGPH20
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
5
States / cities
Scottsdale, Arizona • Encinitas, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Sep 23, 2026, 4:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

NCT04068597
View directory record Official record
Conditions
Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
Interventions
CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax, Bortezomib, Ixazomib, Elranatamab, Teclistamab, Lenalidomide, Daratumumab
Drug
Lead sponsor
CellCentric Ltd.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 23, 2026, 4:29 PM EDT
Completed Phase 4 Interventional Results available

Community Care for Croup (RCT)

NCT01042145
View directory record Official record
Conditions
Croup
Interventions
Prednisone, Dexamethasone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Year to 8 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 14, 2014 · Synced Sep 23, 2026, 4:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

NCT06087653
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Lenalidomide 25 MG Oral Capsule
Drug
Lead sponsor
Starton Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Wilson, North Carolina • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 23, 2026, 4:29 PM EDT
Withdrawn Phase 2 Interventional

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

NCT02578121
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Pomalidomide, Dexamethasone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 23, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

NCT02547662
View directory record Official record
Conditions
Plasma Cell Leukemia, Plasma Cell Myeloma, Plasmacytoma
Interventions
Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Pomalidomide
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Rochester, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 23, 2026, 4:29 PM EDT
Completed Not applicable Interventional Results available

Cortisol Suppression and Startle Responses in Posttraumatic Stress Disorder (PTSD)

NCT01477762
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 23, 2026, 4:29 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane

NCT02995746
View directory record Official record
Conditions
Macular Edema, Epiretinal Membrane, Vitrectomy
Interventions
Dexamethasone
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 23, 2026, 4:29 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina

NCT04976777
View directory record Official record
Conditions
Macular Edema
Interventions
Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
Device · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 23, 2026, 4:29 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dextenza With ILUX for Treatment of MGD

NCT04658927
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Evaporative Dry Eye
Interventions
Dexamethasone, 0.4mg, Prednisone acetate, Control
Drug · Other
Lead sponsor
Warrenville Eyecare
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 23, 2026, 4:29 PM EDT
Recruiting Phase 2 Interventional

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

NCT04991103
View directory record Official record
Conditions
Multiple Myeloma, Amyloidosis
Interventions
DaraVRD/DaraVCD
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 23, 2026, 4:29 PM EDT